摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲氧基-1,5-萘啶 | 1261365-35-8

中文名称
3-甲氧基-1,5-萘啶
中文别名
——
英文名称
3-Methoxy-1,5-naphthyridine
英文别名
——
3-甲氧基-1,5-萘啶化学式
CAS
1261365-35-8
化学式
C9H8N2O
mdl
——
分子量
160.17
InChiKey
GPQLUYHSHWAIPB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    293.5±20.0 °C(Predicted)
  • 密度:
    1.195±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.11
  • 拓扑面积:
    35
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • WGK Germany:
    3

文献信息

  • Aurora Kinase Modulators and Method of Use
    申请人:Amgen Inc.
    公开号:US20140336182A1
    公开(公告)日:2014-11-13
    The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    本发明涉及具有一般式I的化合物,其中A1-8、D'、L1、L2、R1、R6-8和n在此处定义,并且具有调节各种蛋白激酶受体酶并因此影响与这些激酶活动相关的各种疾病状态和病况的能力的合成中间体。例如,这些化合物能够调节枢纽激酶,从而影响细胞周期和细胞增殖过程,以治疗癌症和与癌症相关的疾病。该发明还包括包括这些化合物的药物组合物,以及治疗与枢纽激酶活性相关的疾病状态的方法。
  • TRICYCLIC GYRASE INHIBITORS
    申请人:Bensen Daniel
    公开号:US20120238751A1
    公开(公告)日:2012-09-20
    Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    本文披露了具有式I结构的化合物,以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药,相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
  • [EN] AZA-ELLIPTICINE ANALOGS, METHODS OF SYNTHESIS AND METHODS OF TREATMENT<br/>[FR] ANALOGUES D'AZA-ÉLLIPTICINE, PROCÉDÉS DE SYNTHÈSE ET PROCÉDÉS DE TRAITEMENT
    申请人:MUSC FOUND FOR RES DEV
    公开号:WO2015179218A1
    公开(公告)日:2015-11-26
    In some aspects, the present invention relates to aza-ellipticine compounds of the formula: wherein the variables are as defined herein. The application also provides novel methods of preparing aza-ellipticine compounds, methods of using the compounds, and pharmaceutical compositions thereof.
    在某些方面,本发明涉及式子如下的氮杂-椭圆咔啉化合物:其中变量如本文所定义。该申请还提供了制备氮杂-椭圆咔啉化合物的新方法,使用该化合物的方法和制药组合物。
  • Macrolides
    申请人:Chupak S. Louis
    公开号:US20060135447A1
    公开(公告)日:2006-06-22
    Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.
    本发明涉及以下Macrolide化合物及其定义,以及它们在动物中,包括人类中作为抗菌和抗原虫剂的用途:还公开了制备这些化合物、中间体和药物组成物的方法,以及通过将这些化合物用于需要的主体治疗或预防疾病的方法。此摘要仅为摘录,不限制本发明。
  • Aurora kinase modulators and method of use
    申请人:Cee Victor
    公开号:US20090069297A1
    公开(公告)日:2009-03-12
    The present invention relates to chemical compounds having a general formula I wherein A 1-8 , D′, L 1 , L 2 , R 1 , R 6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.
    本发明涉及具有一般式I的化合物,其中A1-8,D',L1,L2,R1,R6-8和n在此定义,并且合成中间体,它们能够调节各种蛋白激酶受体酶,并因此影响与这些激酶活动相关的各种疾病状态和情况。例如,这些化合物能够调节极化激酶,从而影响细胞周期和细胞增殖过程,以治疗癌症和与癌症相关的疾病。本发明还包括包括这些化合物的药物组合物以及治疗与极化激酶活性相关的疾病状态的方法。
查看更多